Operating
Change in Deferred Revenue
Year-over-year, this metric grew by 94.0%, from -$27.32M to -$1.63M. Over 3 years (FY 2022 to FY 2025), Change in Deferred Revenue shows an upward trend with a -7.1% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
Metric ID:
change_in_deferred_revenueHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$23.94M | -$8.35M | -$12.33M | $0.00 | -$12.47M | -$41.28M | -$8.85M | $21.72M | $24.47M | $17.69M | -$28.56M | -$190.94M | -$3.13M | -$12.81M | -$27.32M | -$13.08M | -$12.54M | $0.00 | -$1.63M |
| QoQ Change | — | +65.1% | -47.6% | +100.0% | — | -231.2% | +78.6% | +345.4% | +12.7% | -27.7% | -261.5% | -568.5% | +98.4% | -309.3% | -113.3% | +52.1% | +4.1% | +100.0% | — |
| YoY Change | — | — | — | +100.0% | -49.2% | — | +28.2% | — | +296.3% | +142.9% | -222.7% | -979.3% | -112.8% | -172.4% | +4.3% | +93.2% | -300.6% | +100.0% | +94.0% |
Range-$190.94M – $24.47M
CAGR-44.9%
Avg YoY Growth-69.9%
Median YoY Growth+16.3%
Current Streak4 quarters growth
Change in Deferred Revenue at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's change in deferred revenue?
- Alnylam Pharmaceuticals (ALNY) reported change in deferred revenue of -$1.63M in Q1 2026.
- How has Alnylam Pharmaceuticals's change in deferred revenue changed year-over-year?
- Alnylam Pharmaceuticals's change in deferred revenue increased by 94.0% year-over-year, from -$27.32M to -$1.63M.
- What is the long-term trend for Alnylam Pharmaceuticals's change in deferred revenue?
- Over 3 years (2022 to 2025), Alnylam Pharmaceuticals's change in deferred revenue has grown at a -7.1% compound annual growth rate (CAGR), from -$66.07M to -$52.94M.